Janux Therapeutics, Inc. (JANX) Financials

JANX Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 1.0 billion 86.7 million
Dec. 31, 2025 1.0 billion 50.7 million
Sept. 30, 2025 1.0 billion 48.2 million
June 30, 2025 1.0 billion 41.7 million

JANX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -12.6 million ?
Dec. 31, 2025 -28.6 million 9.5 million
Sept. 30, 2025 -12.9 million 9.0 million
June 30, 2025 -24.3 million 11.0 million

JANX Net Income

No data available :(

JANX Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 956.4 million - 19.1 million
Dec. 31, 2025 966.6 million - 19.7 million
Sept. 30, 2025 989.0 million - 20.4 million
June 30, 2025 996.0 million - 22.2 million

JANX Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 62.7 million
Dec. 31, 2025 62.0 million
Sept. 30, 2025 62.0 million
June 30, 2025 61.9 million

JANX Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 273000 26.8 million 11.1 million -
Dec. 31, 2025 106000 31.5 million 10.9 million -
Sept. 30, 2025 93000 34.6 million 10.1 million -
June 30, 2025 473000 34.7 million 10.5 million -

JANX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 3.7 million 469000
Dec. 31, 2025 7.9 million 8.9 million
Sept. 30, 2025 10.0 million 501000
June 30, 2025 - 541000

JANX

Price: $15.33

52 week price:
12.12
35.34

Earnings Per Share: -1.84 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 219876

Market Capitalization: 947.7 million

Links: